Challenges of Clinical Trial Design, Conduct & Endpoints Workstream
Back to Task Forces & IDDI Workstreams
The Challenges of Clinical Trial Design, Conduct & Endpoints Workstream aims to provide solutions to complex questions and hot topics in the field:
- What’s the future of clinical trial design?
- How do we transform clinical endpoints into validated regulatory endpoints?
- How can we maximise outcomes for patients participating in these trials?
The Workstream is currently working on synthesising the group’s experience and knowledge of clinical trial designs into a guidance document. We hope this will inspire the next generation of scientists to facilitate the development of novel drugs and treatments for PH patients.
Publications
- Clinical Trial Design in phase 2 and 3 trials for pulmonary hypertension
Sylvia Nikkho, Peter Fernandes, R. James White, Chunqin (CQ) Deng, Harrison W. Farber, Paul A Corris
First Published July 20, 2020
- Role of biomarkers in evaluation, treatment and clinical studies of PAH
Anna Hemnes, Alexander M.K. Rothman, Andrew J. Swift, Lawrence S. Zisman
First Published November 18, 2020
- Novel composite clinical endpoints and risk scores used in clinical trials in PAH
Olivier Sitbon, Sylvia Nikkho, Raymond Benza, Chunqin (CQ) Deng, Harrison W. Farber, Mardi Gomberg-Maitland, Paul Hassoun, Christian Meier, Joanna Pepke-Zaba, Krishna Prasad, Werner Seeger, Paul A Corris
First Published November 18, 2020
- Repurposing of medications for pulmonary arterial hypertension
Mark Toshner, Edda Spiekerkoetter, Harm Bogaard, Georg Hansmann, Sylvia Nikkho, Kurt W. Prins
First Published November 18, 2020
Presentation at PVRI Annual Congress, IDDI Pre-meeting
Leaders
CQ Deng , United Therapeutics Corporation
Harm Jan Bogaard, UMC Amsterdam
Supported by
Ben Lavon , Fluidda
Sylvia Nikkho , Bayer AG
Jason Weatherald, Alberta